Registry study for adults with inherited hATTR amyloidosis mutation
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This study builds a family registry to better understand inherited transthyretin (hATTR) amyloidosis in adults with a confirmed genetic mutation. It may help researchers learn more about the condition and plan future studies, and it requires follow-up visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 18
- Your blood test shows a harmful (pathogenic) hATTR genetic mutation
- Your hATTR mutation was confirmed by a whole-blood genetic test or mass spectrometry
- You are willing and able to come back for required follow-up visits
- You can provide informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people who carry certain TTR gene variants, which can cause a specific type of heart amyloid buildup. It also includes people with symptoms, to understand how the condition develops and how it may be monitored.
This study looks at tiny particles called extracellular vesicles in the blood of people with a specific type of heart amyloidosis. It aims to find better ways to track the disease and predict outcomes.
This study is observing people with amyloidosis or those who carry a specific gene mutation (transthyretin) to learn more about the condition. It does not test any new treatment, but may help researchers understand how the disease affects people.
This study collects information from people with a specific type of heart disease called cardiac amyloidosis (AL or ATTR type). By joining a registry, you help doctors learn more about these conditions and how to better treat them.
This study looks for “biomarkers” (measurable signs in blood or other tests) to understand inherited transthyretin amyloidosis, including in people who have not yet developed symptoms. Results may help researchers track the condition earlier and better understand how it changes over time.
This study follows patients with ATTR amyloidosis over time to understand how the disease affects them. It does not test a new treatment—instead, it asks you to fill out questionnaires about your health and symptoms to help doctors learn more about the condition.
Hear when a new Amyloidosis, Hereditary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.